Synexo Group (SYNEXO) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
20 Aug, 2026Executive summary
Live ARR reached SEK 10.13m in Q2 2026, up 158% year-over-year, with 86% organic growth and SEK 2.83m contributed by Deploi, which was acquired on 26 June.
Signed ARR reached SEK 14.3m, representing a 41% year-over-year increase, with backlog expected to go live in the next twelve months.
The Deploi acquisition expands the platform from BaaS to broader managed infrastructure, enabling cross-sell and further consolidation in the Nordic market.
The Group achieved its first EBITDA-positive month in June, with subsidiary EBITDA at SEK 442k and adjusted Group EBITDA at SEK -188k after one-time costs.
The rights issue was oversubscribed, raising SEK 6.49m before costs, and the Group ended the quarter with SEK 4.5m in cash and no interest-bearing debt.
Financial highlights
Gross margin improved to 74% in Q2 2026, with June exiting at 78%, exceeding the BaaS target of >70%.
Quarterly revenue growth closely tracks ARR growth; Q2 2026 ARR is 102% above LTM revenue.
Statutory net sales were SEK 1.7m for Q2 and SEK 3.0m for H1 2026, compared to SEK 0.1m and SEK 0.2m in the prior year.
Cash-EBITDA turned positive in June, with further expansion expected as ARR backlog converts.
Stable cost base with minor quarterly fluctuations, reflecting listing costs and migration activities.
Outlook and guidance
2026 targets lifted post-Deploi: live ARR >SEK 15.5m and signed ARR >SEK 21.5m by Q4 2026.
Gross margin expected to remain above 70%; Deploi currently at ~60%.
Cash-EBITDA positive on a quarterly basis from Q3 2026 onward.
SEK 4.1m in signed contracts not yet live secures 41% ARR growth before new sales.
Profits to be reinvested in acquisitions or distributed to shareholders, maintaining a solid balance sheet.
Latest events from Synexo Group
- High-growth, profitable BaaS platform with strong retention and disciplined M&A strategy.SYNEXO
Investor presentation - ARR up 76% YoY, gross margin at 66%, and positive subsidiary EBITDA; M&A pipeline advancing.SYNEXO
Q1 2026 - ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 2025 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation - Q3 2025 delivered 56% pro forma revenue growth, 63% gross margin, and strong ARR expansion.SYNEXO
Q3 2025 - No operations remain after subsidiary sale; future depends on a pending data storage acquisition.SYNEXO
Q2 2025 - Sales dropped sharply and losses deepened, with recovery delayed to 2025/2026.SYNEXO
Q3 2024 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 2024 - Sales up, losses persist; MedTech order and new partnerships drive future focus.SYNEXO
Q1 2025